Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Kidney Neoplasms 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 387Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × CB-839 × Clear all
NCT03428217 2023-03-20

CANTATA

Calithera Biosciences, Inc

Phase 2 Completed
444 enrolled 15 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03057600 2022-09-28

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Calithera Biosciences, Inc

Phase 2 Completed
52 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

NCT03163667 2022-09-15

ENTRATA

Calithera Biosciences, Inc

Phase 2 Completed
69 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡